Cargando…

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran

Background: Hepatitis C virus (HCV) infection is a cause of major liver complications, particularly in patients infected with human immunodeficiency virus (HIV). This study aimed to evaluate the efficacy of pegylated interferon (Peg-IFN) and a fixed dose of ribavirin treatment among Iranian HCV mono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hesamizadeh, Khashayar, Tavakoli, Ahmad, Nikbin, Mehri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iran University of Medical Sciences 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708113/ https://www.ncbi.nlm.nih.gov/pubmed/31456987 http://dx.doi.org/10.34171/mjiri.33.63

Ejemplares similares

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal
por: KC, Sudhamshu, et al.
Publicado: (2020)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients
por: Kushner, Lauren E., et al.
Publicado: (2013)

Detection of Parvovirus 4 in Iranian patients with HBV, HCV, HIV mono-infection, HIV and HCV co-infection
por: Rastegarpouyani, Hosna, et al.
Publicado: (2018)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
por: Jamalidoust, Marzieh, et al.
Publicado: (2017)

Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection
por: Aizawa, Yoshio, et al.
Publicado: (2013)

Transcriptomic Assay of CD8(+) T Cells in Treatment-Naïve HIV, HCV-Mono-Infected and HIV/HCV-Co-Infected Chinese
por: Zhao, Jin, et al.
Publicado: (2012)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV
por: Smith, Anton A. A., et al.
Publicado: (2015)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
por: Bhardwaj, Suvercha, et al.
Publicado: (2016)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
por: Beisel, Claudia, et al.
Publicado: (2014)

MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected
por: Cairoli, Victoria, et al.
Publicado: (2023)

Molecular surveillance of HCV mono-infection and HCV-HBV co-infection in symptomatic population at Hyderabad, Pakistan
por: Patoli, Bushra B, et al.
Publicado: (2018)

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Effect of interferon-free therapy on cognition in HCV and HCV/HIV infection: A pilot study
por: Kleefeld, Felix, et al.
Publicado: (2017)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
por: Gupta, Rahul, et al.
Publicado: (2012)

Characterization of the Intestinal Fungal Microbiome in HIV and HCV Mono-Infected or Co-Infected Patients
por: Yin, Yue, et al.
Publicado: (2022)

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
por: Domagalski, K., et al.
Publicado: (2013)

Influence of the HIV GWG variant in the HIV infection progression in mono and HCV coinfected patients
por: Hebeler-Barbosa, Flavia, et al.
Publicado: (2019)

Transcriptional insights into the CD8(+) T cell response in mono-HIV and HCV infection
por: Li, Si-Yao, et al.
Publicado: (2020)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Interferon-λ in HCV Infection and Therapy
por: Pagliaccetti, Nicole E., et al.
Publicado: (2010)

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
por: Chen, Liyu, et al.
Publicado: (2021)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Farcomeni, Stefania, et al.
Publicado: (2021)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals
por: Sehgal, Mohit, et al.
Publicado: (2014)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity
por: Hirosawa, Takuya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5gola68ikid1kanki7tge98un4